Search Technologies
Displaying 51 - 60 of 84 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Use of ClyA Hemolysin for Protein Export and Vaccines
Published Thursday, May 29, 2014The UMB inventor has engineered a novel protein export system for efficiently producing recombinant protein from a host cell, constructed with a genetically stabilized expression plasmid incorporating the protein of interest fused to the ClyA hemolysin of Salmonella enterica serovar Typhi. Used in a live-vector vaccine, this system allows the...
Investigator(s): James Galen
Categories: Therapeutics, Vaccines
Docket: JG-2001-022
-
Broad spectrum antibacterial therapeutic peptides of probiotic origin
Published Thursday, May 29, 2014Bacterial diarrhea still remains the second leading cause of deaths globally, accounting for one fifth of all deaths among children under five. Small bioactive peptides with both Gram-positive and Gram-negative bactericidal activity have been isolated from Lactobacillus GG. These peptides...
Investigator(s): Alessio Fasano, Ruiliang Lu
Categories: Therapeutics, Biologics
Keyword(s): diarrhea, pathogenic bacteria, peptides, probiotic, Lactobacillus, broad spectrum, biologics
Docket: SF-2006-008
-
Total and Phosphorylated IL-1 Receptor-Associated Kinase-1 (IRAK-1) and -4 (IRAK-4) as a Biomarker for Cancer Progression and Chemotherapy Resistance.
Published Thursday, May 29, 2014UMB inventors have identified two proteins active in the TNF receptor-associated factor (TIRAF)/MyD88 pathway, Interleuken-1 Receptor-Associated Kinase (IRAK)-1 and -4, as potential targets for combinatorial therapy reducing chemotherapy resistance in multiple cancer cell lines. IRAK is a...
Investigator(s): Eduardo Davila
Categories: Therapeutics
Keyword(s): chemotherapy, cancer
Docket: ED-2012-072
-
Targeting NAD biosynthesis in bacterial pathogens
Published Thursday, May 29, 2014The increasing incidence of antibiotic-resistant pathogens is a major health crisis, particularly in hospital settings in the developed world. It has been estimated that ~70% of hospital-acquired infections involve multi-antibiotic resistant organisms, resulting in ~90,000 annual deaths at a cost of 4.5ý6.0 billion per year (Burke, 2003)....
Investigator(s): Alexander J MacKerell, Hong Zhang, Andrea L Osterman
Categories: Therapeutics, Small molecules
Keyword(s): biosynthesis, pathogens
Docket: AM-2009-069
-
TWEAK as a Therapeutic Target for Treating Stroke and Other Central Nervous System Diseases
Published Thursday, May 29, 2014Research shows that a TNF-related cytokine known as TWEAK is a causative agent for some of the effects seen in ischemic stroke. When TWEAK binds to a receptor called Fn14 on the surface of neuronal, glial and endothelial cells in the brain, it causes three main effects which result in brain tissue damage: (1) release of pro-inflammatory factors...
Investigator(s): Jeffrey Winkles, Manuel Yepes
Categories: Therapeutics
Keyword(s): stroke, neurovascular
Docket: JW-2005-037
-
Strategy for a Broad-Spectrum Vaccine Against Non-Typhoidal Salmonella
Published Thursday, May 29, 2014On screening sub-Saharan African residents over the last decade for signs of invasive bacterial infection, a high incidence of non-typhoidal Salmonella (NTS) infections was discovered, and these cases were associated with antibiotic resistance and a high mortality of 20-30%. The invasive strains of NTS are dominated by Salmonella Typhimurium...
Investigator(s): Myron Levine, Sharon Tennant, Raphael Simon, James Galen
Categories: Therapeutics, Vaccines
Keyword(s): salmonella, vaccine
Docket: ML-2009-033
-
Small Molecule Inhibitors of BCL6
Published Thursday, May 29, 2014BCL6 is a transcription factor essential for germinal center B-cell development. The BTB domain (also known as the POZ domain) is a common protein-protein interaction motif that is found in over 180 human proteins including BCL6 and has been implicated in many biological processes including central nervous development, oocyte maturation, eye...
Investigator(s): Alexander Donald MacKerell, Jr., Ari M. Melnic, k Gilbert G. Prive
Categories: Therapeutics, Small molecules
Keyword(s): small molecules
Docket: AM-2007-053
-
Small Molecule Inhibitors Of Kynurenine 3-Monooxygenase
Published Thursday, May 29, 2014Kynurenic acid has neuroprotective activities in vivo while the metabolic byproduct of kynurenic acid, quinolinic acid, is neurotoxic. Kynurenine 3-monooxygenase catalyzes the conversion of kynurenine into 3-hydroxykynurenine, a precusor of neurotoxic quinolinic acid. In light the properties of kynurenic acid and quinolinic acid,...
Investigator(s): Robert Schwarcz, Paulo Guidetti
Categories: Therapeutics, Small molecules
Docket: RS-2007-032
-
Prostaglandin D2 metabolites for treatment of optic nerve diseases
Published Wednesday, May 28, 2014Blockage of blood supply to part or all of the optic nerve within the eye can lead to death or dysfunction of optic nerve cells and is termed non-arteritic ischemic optic neuropathy (NAION). NAION is the most common cause of sudden optic nerve related vision loss and affects about 10,000 Americans every year. Currently there is no effective,...
Investigator(s): Steven Lance Bernstein
Categories: Therapeutics, Biologics
Keyword(s): eye, Ophthalmology, stroke, ischemia, neuroprotection, orphan
Docket: SB-2008-026
-
Pluripotent Stem Cell Production Method
Published Wednesday, May 28, 2014One of the major hurdles in stem cell research is that techniques for purification and propagation can be tedious and result in low yields. Standard methods require feeder cells, matrix, and serum, which are expensive and can introduce contaminants. UMB researchers, however, have developed an alternative method to consistently and reliably...
Investigator(s): G. David Trisler, Bernard M. Pessac, Christopher T. Bever Jr., James E. Goolsby
Categories: Research Tools, Antibodies, & Reagents, Therapeutics, Stem Cells
Keyword(s): stem cell
Docket: GT-2004-009